NovoCure Balance Sheet Health
Financial Health criteria checks 4/6
NovoCure has a total shareholder equity of $360.8M and total debt of $654.5M, which brings its debt-to-equity ratio to 181.4%. Its total assets and total liabilities are $1.2B and $861.2M respectively.
Key information
181.4%
Debt to equity ratio
US$654.48m
Debt
| Interest coverage ratio | n/a |
| Cash | US$959.90m |
| Equity | US$360.78m |
| Total liabilities | US$861.21m |
| Total assets | US$1.22b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: N2VC34's short term assets ($1.1B) exceed its short term liabilities ($735.0M).
Long Term Liabilities: N2VC34's short term assets ($1.1B) exceed its long term liabilities ($126.2M).
Debt to Equity History and Analysis
Debt Level: N2VC34 has more cash than its total debt.
Reducing Debt: N2VC34's debt to equity ratio has increased from 78.5% to 181.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: N2VC34 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if N2VC34 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.